Puracyp and Promega Combine Cell Line and Assay Systems for Complete Solution for Drug Developers
Promega and Puracyp team up to provide all-inclusive kits to assess critical pathways researched by drug discovery scientists.
Madison, WI (PRWEB) September 01, 2011
Puracyp Inc. and Promega Corporation have teamed up to provide all-inclusive kits to assess nuclear receptor activation, P450 metabolism, and cellular toxicity during the drug development process. These whole cell assay systems will identify compounds capable of activating nuclear receptors and inducing P450 metabolism while monitoring for cellular toxicity. The assay kits contain components that have been designed and tested to work together in comprehensive user protocols. Puracyp is contributing their proprietary nuclear receptor expressing cell lines, including cells for measuring human PXR activation by potential therapeutic agents. Promega is bringing its leading assay and detection technologies for bioluminescent reporters, cell viability, and P450-Glo substrate-based metabolism assays.
Puracyp and Promega have launched a product line that includes DPX2Ã¢“¢ cells (human PXR), rPXR cells (rodent PXR), MkB3 cells (monkey PXR) and 1A2-DRE cells (human AhR). These cell-based assay systems and those under development (human CAR), are amenable to multiplexing whereby the investigator can assess activation, metabolism, and toxicity in a single well of a 96-well or 384-well plate. Currently, PuracypÃ¢s DPX2Ã¢“¢ stable cell line is the gold standard for assessing PXR activation by NCEs, and is utilized by many leading drug developers to provide pivotal information for predicting human drug-drug interactions. These products are available through the Puracyp website.
Ã¢Å“These kits will allow scientists to answer critical questions about nuclear receptor activation and oxidative drug metabolismÃ¢, said Dr. Jerome Lasker, Director of Laboratory Operations for Puracyp. Puracyp CEO Mark Dale added, Ã¢Å“Nuclear receptor activation and metabolism can be determined in a highly cost-effective manner using PuracypÃ¢s kits.Ã¢ Thomas Livelli, Promega Vice President of Life Sciences Products and Services, commented, Ã¢Å“We believe this new offering will be extremely helpful to scientists and provide high value cell-based systems for discovery and development.Ã¢
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The companyÃ¢s 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global distributors. For more information about Promega, visit http://www.promega.com.
Puracyp is dedicated to providing high quality research products for use in drug discovery and development. The companyÃ¢s primary focus is to provide cell lines enabling rapid determination of a chemicalÃ¢s ability to enhance the expression of drug-metabolizing enzymes and transporters through nuclear receptor activation. Transactivation and metabolism assays had been offered only as a screening service. Now, Puracyp is offering cell lines in kit format for use in individual laboratories. Puracyp was founded in 1999 and is located in Carlsbad, CA, USA. For more information about Puracyp, visit http://www.puracyp.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/9/prweb8710785.htm